拉贝珠单抗
| 单克隆抗体 | |
|---|---|
| 种类 | 完整抗体 |
| 目標 | 癌胚抗原 |
| 臨床資料 | |
| ATC碼 |
|
| 识别信息 | |
| CAS号 | 219649-07-7  |
| ChemSpider |
|
| UNII | |
| KEGG | |
拉贝珠单抗（INN：labetuzumab；商品名CEA-CIDE）是一种人源化IgG1单克隆抗体，用于治疗结直肠癌。[1]它选择性地结合CEACAM5。[2]
该药物还被用在患有转移的甲状腺髓样癌患者中进行了测试。[3]
该药物由Immunomedics开发。
参考资料
- ^ International Nonproprietary Names for Pharmaceutical Substances (INN): Labetuzumab (PDF). WHO Drug Information. 2002, 16 (1): 95 [2024-03-13]. （原始内容存档 (PDF)于2024-07-31）.
- ^ labetuzumab-SN-38 immunoconjugate IMMU-130. National Cancer Institute: NCI Dictionaries. National Institutes of Health, U.S. Department of Health and Human Services. [2024-03-13]. （原始内容存档于2015-05-11）.
- ^ Stein, Rhona; Goldenberg, David M. A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy. Molecular Cancer Therapeutics. 2004-12, 3 (12) [2024-03-13]. ISSN 1535-7163. PMID 15634649. （原始内容存档于2024-03-13）.